Tesamorelin — Growth & Performance
GHRH analog studied in research for visceral-fat and body composition

01

GHRH analog studied in research for visceral adipose tissue and body composition

02

Research has explored its effect on triglycerides and waist circumference

03

Extended half-life vs sermorelin from a trans-3-hexenoic acid modification

Growth & Performance

Tesamorelin

Tesamorelin is a stabilized GHRH analog with a trans-3-hexenoic acid modification that extends its half-life.

15mg vial · 3mg/mL · 5mL99.4% purity

Choose your plan

Peptide checkout

1. Purchase type

2. Choose billing term

How this plan works

Pay

$618.30 today

Renews every 3 months

Ship

Every 3 months

After provider approval

Refills

Paid quarterly

Continues until canceled

Continue with 3-month plan → $618.30

Peptide checkout

Provider review

Ships after approval

A U.S.-licensed provider reviews your request before it ships. If you are not approved, you are refunded in full.

Quick answer

Tesamorelin is a stabilized GHRH analog with a trans-3-hexenoic acid modification that extends its half-life.

Format

Injectable

Best use

Growth & Performance

Evidence

Research-framed

Deep research

About Tesamorelin

Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH) consisting of all 44 amino acids of native GHRH with a trans-3-hexenoic acid moiety conjugated to the tyrosine residue at position 1 via a carbamate linker. This yields a molecular weight of approximately 5,136 Da. The trans-3-hexenoic acid group sterically shields the N-terminal region from dipeptidyl peptidase IV (DPP-IV) cleavage, the primary route of GHRH degradation in vivo, resulting in improved metabolic stability compared to native GHRH and sermorelin.

For reconstitution, lyophilized tesamorelin is reconstituted with sterile water diluent or bacteriostatic water. Research-grade lyophilized powder is stored at -20C for extended periods. Reconstituted solution is refrigerated at 2-8C.

Key benefits

What researchers have looked at

1

GHRH analog studied in research for visceral adipose tissue and body composition

2

Research has explored its effect on triglycerides and waist circumference

3

Extended half-life vs sermorelin from a trans-3-hexenoic acid modification

4

Studied in older adults for measures of verbal memory and executive function

5

Stimulates GH release while pituitary negative feedback remains intact

6

Investigated in research on hepatic fat fraction

7

Binds the GHRH receptor on anterior pituitary somatotrophs

8

Well-characterized pharmacokinetic profile in the published literature

Mechanism

How Tesamorelin is positioned in research

Tesamorelin binds the GHRH receptor on anterior pituitary somatotrophs with affinity comparable to native GHRH and activates the Gs/adenylyl cyclase/cAMP/PKA signaling cascade, stimulating GH gene transcription and vesicular GH release. The trans-3-hexenoic acid modification extends the effective half-life, producing a more sustained GH pulse. Pituitary negative feedback via somatostatin and IGF-1 remains intact. Pharmacokinetics: subcutaneous Tmax ~15-30 minutes, elimination half-life ~26-38 minutes, bioavailability ~4-5%.

Published research

What the research has explored

Tesamorelin has been studied in Phase 3 randomized, double-blind, placebo-controlled trials (LIPO-010 and CTR-1011) for visceral adipose tissue in adults with HIV-associated lipodystrophy, with cognitive measures examined separately by Baker et al. (Archives of Neurology, 2012) in adults aged 55-87 who were healthy or had mild cognitive impairment. A 2019 trial published in Lancet HIV examined hepatic fat fraction over 12 months. Most commonly reported observations in trials were injection site reactions, arthralgia, and peripheral edema.

For research and educational purposes only. References to studies describe published literature and do not constitute medical claims, efficacy guarantees, or treatment recommendations.

Questions people ask

Frequently asked questions

What is Tesamorelin?+

Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH 1-44, MW ~5,136 Da) with a trans-3-hexenoic acid modification that resists DPP-IV cleavage. It is studied in research for body composition and visceral fat.

How does Tesamorelin work?+

It binds the GHRH receptor on pituitary somatotrophs and stimulates physiological GH release through the cAMP/PKA cascade, while somatostatin and IGF-1 feedback remains intact.

What is the pharmacokinetic profile?+

Subcutaneous Tmax is about 15-30 minutes, the elimination half-life is roughly 26-38 minutes (longer than sermorelin), and bioavailability is about 4-5%.